VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp today announced that it will release second quarter financial results on Thursday August 12th at 4:00 p.m. EST (1:00 p.m. PST). Cardiome will hold a teleconference and webcast that same day to discuss the results and to provide an update on developments of the Company. The conference call will be held at 4:30 p.m. EST (1:30 p.m. PST), please dial 416-695-5261 or 1- 877-667-7774 to access the call. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the presentation. The live or archived webcast can be accessed through either http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID(equal sign)880440 or the “What’s New” section of Cardiome’s website at http://www.cardiome.com/.
The conference call will be hosted by Bob Rieder, President and CEO, Doug Janzen, CFO, Christina Yip, VP Finance and Administration, and Don Graham, Director of Corporate Communication.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with three late stage clinical drug programs focused on atrial arrhythmias, congestive heart failure, and hyperuricemia (gout).
Cardiome’s lead antiarrhythmic product, RSD1235, is designed to be an acute-use, intravenous administration treatment for atrial fibrillation (AF), a condition in which the atria of the heart beat rapidly and erratically. RSD1235 selectively blocks ion channels in the heart that are known to be active during episodes of AF. Cardiome currently has three phase 3 studies for intravenous RSD1235 underway. Cardiome expects to initiate clinical studies for the chronic oral therapy of AF by the end of 2004.
Cardiome’s lead drug in the congestive heart failure (CHF) area is oxypurinol, a xanthine oxidase inhibitor. CHF is the failure of the heart to pump blood at a rate sufficient to support the body’s needs. Oxypurinol is currently in a Phase 2 clinical trial. Cardiome also has a program applying its congestive heart failure product, oxypurinol, for the treatment of allopurinol-intolerant gout.
Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME). Further information about Cardiome can be found at http://www.cardiome.com/.
For Further Information: Don Graham Director of Corporate Communication (604) 676-6963 or Toll Free: 1-800-330-9928 Email: dgraham@cardiome.com Forward-Looking Statement Disclaimer
Statements contained in this news release relating to future results, events and expectation are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such statements. Such factors include, among others, those described in the Company’s annual report on Form 20-F. The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
ON BEHALF OF THE BOARD “Robert Rieder” President & Chief Executive Officer
Cardiome Pharma Corp.
CONTACT: Don Graham, Director of CorporateCommunication, (604) 676-6963 or Toll Free: 1-800-330-9928, Email:dgraham@cardiome.com
